Table 1 Randomized trial and non-randomized studies of anti-Ebola therapies

   ZMapp

   PREVAIL II Writing    group, 2016 [24]

Liberia, Sierra Leone, Guinea, USA (11 centres)

ZMapp 50 mg/kg IV every 3 days (n = 36)

Standard care^a (n = 35)

   TKM-130803

   Dunning et al., 2016 [25]

Port Loko, Sierra Leone (1 centre)

TKM-130803 infusion 0.3 mg/kg IV daily for up to 7 days (n = 12)

Standard care^a (n = 3)

   Convalescent whole blood

   Sahr et al., 2017 [26]

Wilberforce and Hastings, Freetown, Sierra Leone (2 centres)

Convalescent whole blood 450 ml (n = 43)

Standard care^a (n = 25)

   Interferon β-1a

   Konde et al., 2017 [27]^b

Coyah, Guinea (1 centre for intervention and the majority of control patients)

Interferon-β-1a 30 μg subcutaneously (n = 9)

Standard care^a (n = 38)

   Convalescent plasma

   van Griensven    et al., 2016 [28]

Conakry, Guinea (1 centre)

Convalescent plasma 200–250 ml (or 10 ml/kg if < 45 kg); two consecutive transfusions with each unit obtained from a separate convalescent donor (n = 84)

Standard care^a (n = 418)

   Favipiravir

   Sissoko et al., 2016 [29]

Guinea (Conakry, Gueokedou, Macenta, Nzerekore) (4 centres for intervention patients; control patients from Guinea)

Favipiravir (oral) 6000 mg on day 0, then 2400 mg daily on days 1 to 9 (n = 111)

Standard care^a (n = 540) ^c

   Favipiravir

   Bai et al., 2016 [30]

Jui Town, Sierra Leone (1 centre)

Favipiravir T-705 (oral) 800 mg twice on day 0 and two doses of 600 mg on subsequent days, ranging from 3 to 11 days, until discharge, transfer, or death (n = 39)

Standard care (IV fluids limited)^a (n = 85)

   Brincidofovir

   Dunning et al., 2016 [31]

Monrovia, Liberia (1 centre)

Brincidofovir (oral) on day 0, 3, 7, 10, and 14 + standard care^a (n = 4)

None

   Artesunate-amodiaquine

   Gignoux et al., 2016 [32]

Foya, Lofa County, Liberia (1 centre)

Artesunate-amodiaquine (n = 71)

Artemether-lumefantrine (n = 194); no anti-malarial drugs (n = 63)